CIK 0001517022 · Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208756903
- Phone
- 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- 8-K Event Results of operations
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market buy CEO and President bought 69,270 shares at $1.25 ($86,588)
- 10-K Report Annual Report
- 8-K Event Results of operations
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale SVP, Chief Accounting Officer sold 49,524 shares at $1.39 ($68,838)
- 4 Planned sale Chief Commercial Officer sold 84,829 shares at $1.39 ($117,912)
- 4 Planned sale SVP, Chief Medical Officer sold 67,658 shares at $1.39 ($94,045)
- 4 Planned sale SVP, Chief Legal Officer sold 69,772 shares at $1.39 ($96,983)
- 4 Planned sale SVP, CFO, CBO & Treasurer sold 34,951 shares at $1.39 ($48,582)
- 4 Planned sale CEO and President sold 341,305 shares at $1.39 ($474,414)
- 4 Grant or award Chief Commercial Officer acquired 204,000 shares (grant or award)
Page 2 of 45 · 886 filings